公开(公告)号：US08303957B2

公开(公告)日：2012-11-06

申请号：US12314218

申请日：2008-12-05

申请人： Hüseyin Firat ,  Pierre Langlade-Demoyan ,  Etienne Vilmer ,  François Lemonnier ,  Pierre Rohrlich ,  Patricia Yotnda

发明人： Hüseyin Firat ,  Pierre Langlade-Demoyan ,  Etienne Vilmer ,  François Lemonnier ,  Pierre Rohrlich ,  Patricia Yotnda

IPC分类号： A61K390/00

CPC分类号： C07K14/4748 ,  A61K38/00 ,  A61K39/00

摘要： The invention concerns the optimization of the wild R9M peptide and the use of the resulting peptides for therapeutic vaccination and/or preventive vaccination against leukaemia in humans. More particularly, the invention concerns mutated immunogenic peptides derived from the human TEL/AML1 fusion protein comprising the wild R9M peptide sequence Arg-Ile-Ala-Glu-Czs-Ile-Leu-Gly-Met. The invention also concerns polynucleotides coding for the mutated R9M immunogenic peptides, cellular expression vectors comprising nucleic acid sequences expressing the mutated R9M immunogenic peptides and polyclonal or monoclonal antibodies capable of being fixed on at least one of said peptides/polynucleotides. The invention further concerns the use of said peptides, polynucleotides and/or antibodies for preparing vaccines, anti-tumoral medicines and compositions and for in vitro and in vivo stimulation of the immune response in humans.

摘要翻译： 本发明涉及野生R9M肽的优化和所得肽用于人类白血病的治疗性接种和/或预防性接种的用途。 更具体地，本发明涉及衍生自包含野生型R9M肽序列Arg-Ile-Ala-Glu-Cys-Ile-Leu-Gly-Met的人TEL / AML1融合蛋白的突变的免疫原性肽。 本发明还涉及编码突变的R9M免疫原性肽的多核苷酸，包含表达突变的R9M免疫原性肽的核酸序列的细胞表达载体和能够固定在至少一种所述肽/多核苷酸上的多克隆或单克隆抗体。 本发明还涉及所述肽，多核苷酸和/或抗体用于制备疫苗，抗肿瘤药物和组合物以及体内和体内刺激人体免疫应答的用途。